[CAS NO. 1001670-19-4] Lagociclovir valactate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1001670-19-4]

Catalog

HY-107026

Brand

MCE

CAS

1001670-19-4

DESCRIPTION [1001670-19-4]

Overview

MDL	-
Molecular Weight	454.45
Molecular Formula	C19H27FN6O6
SMILES	O=C1C2=C(NC(N)=N1)N([C@](C[C@@H]3F)(C)O[C@@H]3COC([C@H](C)OC([C@@H](N)C(C)C)=O)=O)C=N2

For research use only. We do not sell to patients.

Summary

Lagociclovir valactate is a prodrug of Lagociclovir (HY-14844). Lagociclovir valactate is an orally active anti- HBV agent ^[1] .

IC50 & Target

HBV ^[1]

In Vivo

Lagociclovir valactate (20 or 60 mg/kg; p.o.; daily for 10 weeks) shows anti-woodchuck hepatitis virus (WHV) activity in woodchucks ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Woodchucks with chronic WHV infection ^[1]
Dosage:	20 or 60 mg/kg
Administration:	Oral, daily for 10 weeks
Result:	Reduced WHV viremia effectively and maintained WHV DNA at a very low level.

Animal Model:

Woodchucks ^[1]

Dosage:

10 or 40 mg/kg

Administration:

Oral (Pharmacokinetic Analysis)

Result:

Average pharmacokinetic parameters for Lagociclovir after oral administration of Lagociclovir valactate to healthy and chronically WHV infected woodchucks ^[1]

Pharmacokinetic parameter for Lagociclovir	Healthy woodchucks (n = 4) receiving Lagociclovir valactate at 10 mg/kg	Healthy woodchucks (n = 4) receiving Lagociclovir valactate at 40 mg/kg	WHV-infected woodchucks (n = 14) receiving Lagociclovir valactate at 60 mg/kg
C _max (μM)	0.54 ± 0.14	2.10 ± 1.5	3.50 ± 1.9
T _max (h)	4.10 ± 1.0	3.30 ± 1.5	2.90 ± 1.1
AUC _0-∞ (μM • h/liter)	5.15 ± 1.0	10.50 ± 4.2	20.1 ± 11.3
t _1/2 (h)	5.44 ± 1.2	4.20 ± 1.6	4.7 ± 0.8

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Michalak TI, et al. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother. 2009 Sep;53(9):3803-14.